Android app on Google Play

Leerink Swann Starts Trius Therapeutics (TSRX) at Outperform, Sees a More than Double

November 27, 2012 7:58 AM EST Send to a Friend
Get Alerts TSRX Hot Sheet
Price: $13.63 --0%

Rating Summary:
    11 Buy, 3 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 24 | New: 21
Trade TSRX Now!
Join SI Premium – FREE
Leerink Swann initiates coverage on Trius Therapeutics (NASDAQ: TSRX) with a Outperform. PT $10.00.

The firm comments, "Lead drug candidate Tedizolid (TZD) is increasingly differentiated from PFE’s (MP) market leader Linezolid (LZD), which should allow TSRX to successfully launch and maintain premium pricing for TZD even after LZD becomes generic in 2015. MEDACorp KOLs believe TZD’s key differentiation from LZD relates to: (1) improved hematologic profile (less myelosuppression);
(2) lack of drug-drug-interactions (DDI), and (3) an improved resistance profile. Our base case valuation assumes TZD maintains premium pricing and conservatively leads to our $10 DCF valuation. A worst case scenario (not our valuation) assumes TZD is priced in line with generic LZD and leads to a ~$4.50 estimate, which provides minimal downside from current levels."

For an analyst ratings summary and ratings history on Trius Therapeutics click here. For more ratings news on Trius Therapeutics click here.

Shares of Trius Therapeutics closed at $4.91 yesterday.




You May Also Be Interested In


Related Categories

Hot New Coverage, New Coverage

Add Your Comment